Subconjunctival bevacizumab induces regression of corneal neovascularisation: A pilot randomised placebo-controlled double-masked trial

British Journal of Ophthalmology

Volumn 97, Issue 1, 2013, Pages 28-32

  Petsoglou, Constantinos ^a   Balaggan, Kamaljit S ^a   Dart, John K G ^a,b   Bunce, Catey ^a   Xing, Wen ^a   Ali, Robin R ^b   Tuft, Stephen J ^a,b  

^a MOORFIELDS EYE HOSPITAL   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; DEXAMETHASONE; PLACEBO;

ADULT; ARTICLE; CELL COUNT; CLINICAL ARTICLE; CONJUNCTIVAL HEMORRHAGE; CONTROLLED STUDY; CORNEA DISEASE; CORNEA NEOVASCULARIZATION; CORNEA THICKNESS; CORNEA TRANSPLANTATION; CORNEAL EPITHELIAL DEFECT; DOUBLE BLIND PROCEDURE; ENDOTHELIUM CELL; FEMALE; GRAFT REJECTION; HUMAN; INTRAOCULAR PRESSURE; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REMISSION; TREATMENT OUTCOME; VISUAL ACUITY;

ADULT; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; CELL COUNT; CONJUNCTIVA; CORNEAL NEOVASCULARIZATION; CORNEAL PACHYMETRY; DOUBLE-BLIND METHOD; ENDOTHELIUM, CORNEAL; FEMALE; HUMANS; INTRAOCULAR PRESSURE; MALE; MIDDLE AGED; OFF-LABEL USE; PILOT PROJECTS; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY;

EID: 84872272757     PISSN: 00071161     EISSN: 14682079     Source Type: Journal    
DOI: 10.1136/bjophthalmol-2012-302137     Document Type: Article

References (29)

1. Chang J, Gabison E, Kato T, et al. Corneal Neovascularization. Curr Opin Ophthalmol 2001;12:242-9. (Pubitemid 32751680)
2. Bachmann B, Taylor RS, Cursiefen C. Corneal neovascularization as a risk factor for graft failure and rejection after keratoplasty: an evidence-based meta-analysis. Ophthalmology 2010;117:1300-5.
3. Maddula S, Davis DK, Burrow MK, et al. Horizons in therapy for corneal angiogenesis. Ophthalmology 2011;118:591-9.
4. Cursiefen C, Colin J, Dana R, et al. Consensus statement on indications for anti-angiogenic therapy in the management of corneal diseases associated with neovascularisation: outcome of an expert roundtable. Br J Ophthalmol 2012;96:3-9.
5. Amano S, Rohan R, Kuroki M, et al. Requirement for vascular endothelial growth factor in wound- and inflammation-related corneal neovascularization. Invest Ophthalmol Vis Sci 1998;39:18-22. (Pubitemid 28040457)
6. Philipp W, Speicher L, Humpel C. Expression of vascular endothelial growth factor and its receptors in inflammed and vascularized human corneas. Invest Ophthalmol Vis Sci 2000;41:2514-22. (Pubitemid 30624378)
7. Ambati B, Nozaki M, Singh N, et al. Corneal avascularity is due to soluable VEGF receptor-1. Nature 2006;443:993-7. (Pubitemid 44646176)
8. Chen W-L, Chen Y-M, Chu H-S, et al. Bevacizumab for the treatment of corneal neovascularization. Cornea 2009;28(Suppl. 1):S26-30.
9. DeStafeno JJ, Kim T. Topical bevacizumab therapy for corneal neovascularization. Arch Ophthalmol 2007;125:834-6. (Pubitemid 46919748)
10. Dastjerdi MH, Al-Arfaj KM, Nallasamy N, et al. Topical bevacizumab in the treatment of corneal neovascularization: results of a prospective, open-label, noncomparative study. Arch Ophthalmol 2009;127:381-9.
11. Harooni H, Reddy V, Root T, et al. Bevacizumab for graft rejection. Ophthalmology 2007;114:1950.
12. Erdurmus M, Totan Y. Subconjunctival bevacizumab for corneal neovascularization. Graefes Arch Clin Exp Ophthalmol 2007;245:1577-9. (Pubitemid 47423342)
13. Awadein A. Subconjunctival bevacizumab for vascularized rejected corneal grafts. J Cat Refract Surg 2007;33:1991-3. (Pubitemid 47615364)
14. Benayoun Y, Adenis JP, Casse G, et al. Effects of subconjunctival bevacizumab on corneal neovascularization: results of a prospective study. Cornea 2012;31:937-44.
15. Bock F, Onderka J, Hos D, et al. Improved semiautomatic method for morphometry of angiogenesis and lymphangiogenesis in corneal flatmounts. Exp Eye Res 2008;87:462-70.
16. Koenig Y, Bock F, Horn F, et al. Short- and long-term safety profile and efficacy of topical bevacizumab (Avastin) eye drops against corneal neovascularization. Graefes Arch Clin Exp Ophthalmol 2009;247:1375-82.
17. Nomoto H, Shiraga F, Kuno N, et al. Pharmacokinetics of bevacizumab after topical, subconjunctival, and intravitreal administration in rabbits. Invest Ophthalmol Vis Sci 2009;50:4807-13.
18. Brereton HM, Taylor SD, Farrall A, et al. Influence of format on in vitro penetration of antibody fragments through porcine cornea. Br J Ophthalmol. 2005;89:1205-9. (Pubitemid 41224476)
19. Dastjerdi MH, Sadrai Z, Saban DR, et al. Corneal penetration of topical and subconjunctival bevacizumab. Invest Ophthalmol Vis Sci 2011;52:8718-23.
20. Ahmed A, Berati H, Nalan A, et al. Effect of bevacizumab on corneal neovascularization in experimental rabbit model. Clin Exp Ophthalmol 2009;37:730-6.
21. Hashemian MN, Z-Mehrjardi H, Moghimi S, et al. Prevention of corneal neovascularization: comparison of different doses of subconjunctival bevacizumab with its topical form in experimental rats. Ophthalmic Res 2011;46:50-4.
22. Wang Y, Fei D, Vanderlaan M, et al. Biological activity of bevacizumab, a humanized anti-VEGF antibody in vitro. Angiogenesis 2004;7:335-45. (Pubitemid 40767935)
23. Shima C, Sakaguchi H, Gomi F, et al. Complications in patients after intravitreal injection of bevacizumab. Acta Ophthalogica 2008;86:372-6.
24. Bahar I, Kaiserman I, McAllum P, et al. Subconjunctival bevacizumab injection for corneal neovascularization in recurrent pterygium. Curr Eye Res 2008;33:23-8. (Pubitemid 351156952)
25. Papathanassiou M, Theodossiadis PG, Liarakos VS, et al. Inhibition of corneal neovascularization by subconjunctival bevacizumab in an animal model. Am J Ophthalmol 2008;145:424-31.
26. Cursiefen C, Wenkel H, Martus P, et al . Impact of short-term versus long-term topical steroids on corneal neovascularization after non-high-risk keratoplasty. Graefes Arch Clin Exp Ophthalmol 2001;239:514-21. (Pubitemid 32725422)
27. Andrieu-Soler C, Berdugo M, Doat M, et al. Downregulation of IRS-1 expression causes inhibition of corneal angiogenesis.(Erratum appears in Invest Ophthalmol Vis Sci. 2006 May;47:1784). Invest Ophthalmol Vis Sci 2005;46:4072-8.
28. Beurskens AJ, de Vet HC, Kant I. (Roaming through the methodology. VIII. Pilot studies: sense and nonsense). Ned Tijdschr Geneeskd 1998;142:2142-5. (Pubitemid 28445117)
29. Conn VS, Algase DL, Rawl SM, et al. Publishing pilot intervention work. West J Nurs Res 2010;32:994-1010.